Genomic Hallmarks of Localized, Non-indolent Prostate Cancer

Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastatic disease. Rather, a significant proportion of tumours harboured recurrent non-coding aberrations, large-scale genomic rearrangements, and alterations in which an inversion repressed transcription within its boundaries. Local hypermutation events were frequent, and correlated with specific genomic profiles. Numerous molecular aberrations were prognostic for disease recurrence, including several DNA methylation events, and a signature comprised of these aberrations outperformed well-described prognostic biomarkers. We suggest that intensified treatment of genomically aggressive localized prostate cancer may improve cure rates.

Citing Articles

Unveiling Racial Disparities in Localized Prostate Cancer: A Systems-Level Exploration of the lncRNA Landscape.

Morgan R, Hazard E, Savage S, Halbert C, Gattoni-Celli S, Hardiman G Genes (Basel). 2025; 16(2).

PMID: 40004558 PMC: 11855151. DOI: 10.3390/genes16020229.

The Landscape of Prostate Tumour Methylation.

Arbet J, Yamaguchi T, Shiah Y, Hugh-White R, Wiggins A, Oh J bioRxiv. 2025; .

PMID: 39990314 PMC: 11844408. DOI: 10.1101/2025.02.07.637178.

The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.

Pedrani M, Barizzi J, Salfi G, Nepote A, Testi I, Merler S Int J Mol Sci. 2025; 26(1.

PMID: 39796175 PMC: 11719667. DOI: 10.3390/ijms26010318.

EHMT2-mediated R-loop formation promotes the malignant progression of prostate cancer via activating Aurora B.

Zhang Y, Su M, Chen Y, Cui L, Xia W, Xu R Clin Transl Med. 2025; 15(1):e70164.

PMID: 39763034 PMC: 11705492. DOI: 10.1002/ctm2.70164.

Unveiling the molecular profile of a prostate carcinoma: implications for personalized medicine.

Agostini M, Giacobbi E, Servadei F, Bishof J, Funke L, Sica G Biol Direct. 2024; 19(1):146.

PMID: 39741346 PMC: 11686862. DOI: 10.1186/s13062-024-00492-z.

References

Gerstein M, Kundaje A, Hariharan M, Landt S, Yan K, Cheng C . Architecture of the human regulatory network derived from ENCODE data. Nature. 2012; 489(7414):91-100. PMC: 4154057. DOI: 10.1038/nature11245. View

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

Schiewer M, Goodwin J, Han S, Brenner J, Augello M, Dean J . Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012; 2(12):1134-49. PMC: 3519969. DOI: 10.1158/2159-8290.CD-12-0120. View

Berger M, Lawrence M, Demichelis F, Drier Y, Cibulskis K, Sivachenko A . The genomic complexity of primary human prostate cancer. Nature. 2011; 470(7333):214-20. PMC: 3075885. DOI: 10.1038/nature09744. View

Nikiforova M, Stringer J, Blough R, Medvedovic M, Fagin J, Nikiforov Y . Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science. 2000; 290(5489):138-41. DOI: 10.1126/science.290.5489.138. View

Govind S, Zia A, Hennings-Yeomans P, Watson J, Fraser M, Anghel C . ShatterProof: operational detection and quantification of chromothripsis. BMC Bioinformatics. 2014; 15:78. PMC: 3999944. DOI: 10.1186/1471-2105-15-78. View

Massie C, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L . The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011; 30(13):2719-33. PMC: 3155295. DOI: 10.1038/emboj.2011.158. View

DAmico A, Moul J, Carroll P, Sun L, Lubeck D, Chen M . Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003; 21(11):2163-72. DOI: 10.1200/JCO.2003.01.075. View

Korbel J, Campbell P . Criteria for inference of chromothripsis in cancer genomes. Cell. 2013; 152(6):1226-36. DOI: 10.1016/j.cell.2013.02.023. View

10.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

11.

Cooper C, Eeles R, Wedge D, Van Loo P, Gundem G, Alexandrov L . Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet. 2015; 47(4):367-372. PMC: 4380509. DOI: 10.1038/ng.3221. View

12.

Buyyounouski M, Pickles T, Kestin L, Allison R, Williams S . Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol. 2012; 30(15):1857-63. DOI: 10.1200/JCO.2011.35.1924. View

13.

Feng F, de Bono J, Rubin M, Knudsen K . Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Mol Cell. 2015; 58(6):925-34. PMC: 4487541. DOI: 10.1016/j.molcel.2015.04.016. View

14.

Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D . Circos: an information aesthetic for comparative genomics. Genome Res. 2009; 19(9):1639-45. PMC: 2752132. DOI: 10.1101/gr.092759.109. View

15.

Lalonde E, Ishkanian A, Sykes J, Fraser M, Ross-Adams H, Erho N . Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 2014; 15(13):1521-1532. DOI: 10.1016/S1470-2045(14)71021-6. View

16.

Sherry S, Ward M, Kholodov M, Baker J, Phan L, Smigielski E . dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2000; 29(1):308-11. PMC: 29783. DOI: 10.1093/nar/29.1.308. View

17.

Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S . Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2014; 33(3):272-7. DOI: 10.1200/JCO.2014.55.1192. View

18.

Lawrence M, Stojanov P, Mermel C, Robinson J, Garraway L, Golub T . Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505(7484):495-501. PMC: 4048962. DOI: 10.1038/nature12912. View

19.

Ewing A, Houlahan K, Hu Y, Ellrott K, Caloian C, Yamaguchi T . Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. Nat Methods. 2015; 12(7):623-30. PMC: 4856034. DOI: 10.1038/nmeth.3407. View

20.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View